TY - JOUR T1 - The impact of comorbidities related to BMI in COPD patients JF - European Respiratory Journal JO - Eur Respir J VL - 38 IS - Suppl 55 SP - p3587 AU - Carlos Cabrera Lopez AU - Jorge Zagaceta AU - Claudia Cote AU - Miguel Divo AU - Juan Pablo De Torres AU - José María Marín AU - Ciro Casanova AU - Victor Pinto-Plata AU - Javier Zulueta AU - Bartolomé Celli AU - Santiago Carrizo Y1 - 2011/09/01 UR - http://erj.ersjournals.com/content/38/Suppl_55/p3587.abstract N2 - Introduction: In COPD patients a higher BMI is associated with better survival (the obesity paradox). The mechanism of this paradox is not well understood. We explored whether different co-morbidities related to survival in patients with different BMI.Methods: We followed 1664 COPD patients of the BODE cohort. A total of 80 comorbidities were systematically recorded. Comorbidities prevalence and association with mortality was explored using Cox proportional hazard stratified by BMI in four groups (≤ 21, 22-29, 30-35, ≥ 36 kg/m2).Results: COPD patients with BMI ≥ 36 had significantly more comorbidities than the other groups but they had lower mortality, better FEV1 and lower BODE.View this table:No specific co-morbidities had an independent association with mortality in this group whereas they did in the other subsets. Patients with a BMI between 22 and 35 had the most number of comorbidities associated with death.Conclusion: In COPD, obese patients (BMI>36) have a better survival than non-obese patients, in spite of having more co-morbidities. In these obese patients there was no co-morbidity that was significantly and independently associated with mortality. ER -